EPAZ - Nano Caps With Big Breakout Potential (EPAZ HNRC KRBP NLTX)
(NewsDirect)
Penny stock tradingcan offer investors an exciting opportunity to potentially reapsignificant gains. While a lot of investors might concentrate on morewell-known stocks listed on significant exchanges, there are a ton oflow-priced stocks that are currently trading that may offer promisinginvestment potential.
In this article, we'll be delving into the world of pennystock trading and examining four stocks that are currently trading atattractive prices. These stocks could have the potential to experienceexplosive growth, and we'll be taking a closer look at what thesecompanies offer.
While investing in penny stocks can come with increased risk,it also presents the opportunity for big rewards. As investors,it's important to carefully analyze the potential of each stockand assess their long-term prospects.
Penny stocks offer an exciting opportunity toinvest in promising companies at a low price. Let's explore whatthese four stocks have to offer and why they may be worth consideringfor your portfolio.
Epazz Inc. (OTCMKTS: EPAZ) is a mission-criticalprovider of drone technology, blockchain mobile apps, and cloud-basedbusiness software solutions. On March 7, Epazz announced that thecompany received the official utility patent on their AI-predictivedrone Smart Charging Pad.
This now allows EPAZ to seek international patents usingestablished U.S. patent treaties. They will concentrate on patentregistration in Ukraine, the United Kingdom, the European Union,Canada, Australia, South Africa, and Brazil.
EPAZ believes that theSmart Charging Pad is a major game changer in the drone chargingarena. While most competitors are pricing their charging pads fordrones weighing less than 55 pounds anywhere from $4,000 to $15,000,the ZenaDrone Smart Charging Pad, which can be used to charge ourZenaDrone 1000, weighing over 250 pounds, will be priced at less than$15,000.
TheZenaDrone Smart Charging Pad allows the ZenaDrone 1000 to land on thecharger for automatic charging. This allows the drone to be used inremote areas and operate in a true autonomous fashion. According tothe company, the Smart Charging Pad has built-in computer vision tohelp it understand the environment around it and select the bestoption for receiving energy. It also has options for solar panels orwind power.
TheZenaDrone 1000, with its updated artificial intelligence (AI)predictive automation software, is a serious aircraft created for useby the military as well as in the oil and gas and agricultureindustries. The ZenaDrone is meant to be a workhorse and to push thelimits of future technology available today. The company'saffordable offerings are getting noticed quickly.
Just a few weeks ago,back in February, EPAZ submitted Phase 1 SBIR proposals to the U.S.government. If ZenaDrone is awarded a Phase 1 contract, which has avalue of up to $75,000 per proposal, the company will then be able tosubmit for Phase 2 contracts, which have a value of up to $1.2 millionper contract. ZenaDrone will hear back from the government in 90 days.
Additional phasesof the SBIR would give the business the opportunity to securesignificant government contracts worth up to $15 million over thefollowing three years. The company's prospects are also improvedby the US government's ban on Chinese drones, which coincides withthe significant revenue opportunity provided by SBIR contracts in theupcoming years. A further benefit of joining the program is thatZenaDrone will be permitted to sell its drones to US allies.
With the US Militarydrone segment set to expand, and the potential for big revenue overthe next few years, EPAZ should be on the list of any investor lookingfor a promising penny stock
Houston Natural Resources Corp. (OTCMKTS:HNRC) is a diversified energy company with oil and gas interestsas well as wastewater treatment facilities. The Halff Oil Field inCrockett County, Texas, has 83 oil wells with an estimated 33 millionbarrels of oil and water treatment and appraised reserves of $69million. HNRC has acquired a 9.9% interest in Cunningham Energy LLC,which has an appraised reserve of $352 million.
On Tuesday, HNRCannounced record results for the quarter ending in December 2022. HNRCincreased revenue by 12.6% over 2021. Their total earnings increasedby 24.9% over the previous year. Earnings per share for 2022 were $0.14 per share. HNRC has a net asset value of $ 1.35 per share as ofDecember 31, 2022.
Frank Kristan, president of Houston Natural Resources Corp.,commented, "The company's increase in revenues and earningshas been due to acquisitions and an increase in services it providesto its portfolio companies. The company sponsored a successful $86million NYSE listing of an energy focused special purpose acquisitioncorporation in 2022 and acquired an interest in Cunningham Energy. Weanticipate consistent growth from revenue and profit in 2023 inaddition to other liquidity events for HNRC shareholders.
While the stock finishedTuesday up nearly 75%, ultimately it could not carry the momentum intoWednesday, and the stock fell 22.66%.
Keep it on your shortlist for potentialbreakouts.
Kiromic BioPharma Inc. (NASDAQ: KRBP) is aclinical-stage biotherapeutics company using its proprietary DIAMONDartificial intelligence 2.0 target discovery engine to detect,develop, and commercialize cell therapies with a therapeutic focus onimmuno-oncology
Last week, the company celebrated a victory when they releasedpromising news regarding a preclinical trial. According to KRBP, thecompany received favorable safety results from the histopathologyevaluation of a preclinical study of the pharmacology of KB-GDT-01(trademark: Deltacel) administered alone and in combination with anon-biological anti-tumor therapy in mice.
“These findings are in line with what weobserved in a study evaluating Deltacel monotherapy at a dose morethan 7 times higher than the maximum dose planned for the Deltacelclinical trial, and they confirm that Deltacel was well tolerated inmice, even when given as part of a combination therapy that furtherboosted its potency,” said Leonardo Mirandola, Ph.D., ChiefScientific Officer of Kiromic BioPharma.
Kiromic plans to submit the Deltacel INDapplication to the FDA in the current first quarter. If accepted,plans call for the activation of the clinical trial process to beginin the second quarter of 2023. The planned clinical study willevaluate Deltacel in combination with a non-biological anti-tumortherapy for the treatment of non-small cell lung cancer.'
The stock finished up12.59% on Wednesday.
A big winner from Wednesday's after hours trading sessionis Neoleukin Therapeutics Inc. (NASDAQ: NLTX) . Thisbiopharmaceutical company uses "de novo" protein designtechnology to develop next-generation immunotherapies for cancer,inflammation, and autoimmunity.
Neoleukin employs sophisticated computationalmethods to create proteins with specific pharmaceutical propertiesthat may provide a therapeutic advantage over native proteins.
NLTX announced earlierthis week that it had hired SVB Securities to help it review strategicoptions for the business with the aim of increasing shareholder value.Neoleukin's Board of Directors approved a further corporaterestructuring to conserve cash, which included a 70% reduction in thecompany's workforce, in connection with the evaluation ofstrategic alternatives. CEO Jonathan Drachman, M.D., will also bestepping down after a short transition. The company anticipates thatthis force reduction will be finished in the first half of 2023.
Razorpitch Inc. is a marketingcommunications and investor relations firm serving private, pre-IPO,and public companies. RazorPitch specializes in corporate, investor,and stakeholder communications. Our goal is to raise visibility,expand awareness, and increase value. To learn more, visit RazorPitch.com.
Disclaimers:The Private Securities Litigation Reform Act of 1995 providesinvestors a safe harbor in regard to forward-looking statements. Anystatements that express or involve discussions with respect topredictions, expectations, beliefs, plans, projections, assumptions,objectives, goals, assumptions of future events or performance are notstatements of historical fact may be forward looking statements.Forward looking statements are based on expectations, estimates, andprojections at the time the statements are made that involve a numberof risks and uncertainties which could cause actual results or eventsto differ materially from those presently anticipated. Forward lookingstatements in this action may be identified through use of words suchas projects, foresee, expects, will, anticipates, estimates, believes,understands, or that by statements, indicating certain actions "es; may, could or might occur Understand there is no guaranteepast performance is indicative of future results. Investing inmicro-cap or growth securities is highly speculative and carries anextremely high degree of risk. It is possible that an investor'sinvestment may be lost or due to the speculative nature of thecompanies profiled. RazorPitch is responsible for the production anddistribution of this content. RazorPitch is not operated by a licensedbroker, a dealer, or a registered investment advisor. It should beexpressly understood that under no circumstances does any informationpublished herein represent a recommendation to buy or sell asecurity.
Contact Details
Mark McKelvie
+1585-301-7700
CompanyWebsite
Copyright (c) 2023 TheNewswire - All rights reserved.